Target Name: CD209
NCBI ID: G30835
Other Name(s): CD209 molecule, transcript variant 7 | CD209 variant 3 | CD209 molecule, transcript variant 6 | HIV gpl20-binding protein | C-type lectin domain family 4 member L | CD209_HUMAN | CD209 variant 1 | CD209 antigen (isoform 1) | DC-SIGN | CD209 antigen (isoform 3) | CD209 molecule, transcript variant 5 | dendritic cell-specific intercellular adhesion molecule-3-grabbing non-integrin | CD209 antigen | DCSIGN | CD209 molecule, transcript variant 4 | CD209 molecule | CD209 variant 6 | Dendritic Cells-Specific ICAM-3 Grabbing Non-integrin | CDSIGN | CD209 antigen (isoform 6) | CD209 molecule, transcript variant 1 | Dendritic cell-specific ICAM-3-grabbing non-integrin 1 | CLEC4L | CD209 variant 5 | CD209 antigen (isoform 5) | CD209 antigen (isoform 4) | dendritic cell-specific intracellular adhesion molecules (ICAM)-3 grabbing non-integrin | dendritic cell-specific ICAM-3-grabbing non-integrin 1 | DC-SIGN1 | CD209 molecule, transcript variant 3 | hDC-SIGN | CD209 variant 4 | CD209 antigen (isoform 7) | CD209 variant 7

CD209: A Potential Drug Target and Biomarker

CD209, also known as human CD20 antigen 9, is a type-I transmembrane protein that is expressed in various tissues and cell types, including B cells, including mature and memory B cells. It is a glycoprotein with a molecular weight of approximately 21 kDa and a monomeric structure composed of two constant and two variable regions. CD209 is a potential drug target and biomarker for various diseases, including cancer, autoimmune disorders, and neurodegenerative diseases.

CD209 is involved in various cellular processes, including cell adhesion, migration, and signaling. It is a critical receptor for the B cell receptor (BCR), also known as the B cell antigens (BCR) or CD209 antigen. The BCR is a transmembrane protein that plays a central role in the development and function of B cells, including their proliferation, differentiation, and selection. The BCR is composed of two constant and two variable regions, with the variable region containing the antigens specific for the CD209 receptor.

CD209 has been identified as a potential drug target due to its unique structure and its involvement in various cellular processes. Several studies have shown that CD209 is a good candidate for small molecule inhibitors, including inhibitors that can modulate the activity of the BCR. These inhibitors have the potential to treat various diseases, including cancer, autoimmune disorders, and neurodegenerative diseases.

One of the main advantages of CD209 as a drug target is its expression in various tissues and cell types, including B cells. This makes it a potential target for small molecule inhibitors that can affect the behavior of B cells, including their proliferation, differentiation, and survival. Additionally, CD209 is involved in various cellular processes that are critical for the development and function of B cells, including cell adhesion, migration, and signaling. This means that any inhibitor that targets CD209 may have a broad range of effects on B cell behavior and function.

CD209 has also been shown to be involved in the regulation of cancer cell growth and metastasis. Several studies have shown that CD209 is a critical regulator of cancer cell growth, including the regulation of cell cycle progression and the inhibition of apoptosis. In addition, CD209 has been shown to play a role in the regulation of stem cell proliferation and the maintenance of stem cell self-renewal. These findings suggest that CD209 may be a useful target for cancer therapies that target stem cells and cell cycle regulation.

CD209 has also been identified as a potential biomarker for various diseases, including cancer. Several studies have shown that CD209 is expressed in various tissues and cell types, including cancer cells. This makes it a potential biomarker for cancer, including the detection and diagnosis of early-stage cancer. In addition, some studies have shown that CD209 can be used as a therapeutic target for cancer, including the inhibition of CD209-mediated signaling pathways. These findings suggest that CD209 may be a useful target for cancer diagnostics and therapies.

In conclusion, CD209 is a potential drug target and biomarker for various diseases, including cancer, autoimmune disorders, and neurodegenerative diseases. Its unique structure and involvement in various cellular processes make it an attractive target for small molecule inhibitors. Further research is needed to fully understand the role of CD209 as a drug target and biomarker, and to develop effective therapies that target this protein.

Protein Name: CD209 Molecule

Functions: Pathogen-recognition receptor expressed on the surface of immature dendritic cells (DCs) and involved in initiation of primary immune response. Thought to mediate the endocytosis of pathogens which are subsequently degraded in lysosomal compartments. The receptor returns to the cell membrane surface and the pathogen-derived antigens are presented to resting T-cells via MHC class II proteins to initiate the adaptive immune response

More Common Targets

CD22 | CD226 | CD24 | CD244 | CD247 | CD248 | CD24P2 | CD27 | CD27-AS1 | CD274 | CD276 | CD28 | CD2AP | CD2BP2 | CD3 Complex (T Cell Receptor Complex) | CD300A | CD300C | CD300E | CD300LB | CD300LD | CD300LD-AS1 | CD300LF | CD300LG | CD302 | CD320 | CD33 | CD34 | CD36 | CD37 | CD38 | CD3D | CD3E | CD3G | CD4 | CD40 | CD40LG | CD44 | CD44-DT | CD46 | CD47 | CD48 | CD5 | CD52 | CD53 | CD55 | CD58 | CD59 | CD5L | CD6 | CD63 | CD68 | CD69 | CD7 | CD70 | CD72 | CD74 | CD79A | CD79B | CD8 | CD80 | CD81 | CD81-AS1 | CD82 | CD83 | CD84 | CD86 | CD8A | CD8B | CD8B2 | CD9 | CD93 | CD96 | CD99 | CD99L2 | CD99P1 | CDA | CDADC1 | CDAN1 | CDC123 | CDC14A | CDC14B | CDC14C | CDC16 | CDC20 | CDC20-DT | CDC20B | CDC20P1 | CDC23 | CDC25A | CDC25B | CDC25C | CDC26 | CDC27 | CDC27P2 | CDC34 | CDC37 | CDC37L1 | CDC37P1 | CDC40 | CDC42